• STAT+: Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug succeeds in closely watched trial

    5 days ago - By STAT

    Everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. Our choice today is, once again, maple bourbon. And as you know, a prescription is not required. So feel free to indulge as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day, and, as always, do drop us a line when you hear something interesting....
    In a significant victory for AbbVie, a U.S. appeals...
    Read more ...

     

  • STAT+: Alnylam therapy for increasingly common heart disease succeeds in closely watched trial

    5 days ago - By STAT

    Alnylam Pharmaceuticals' treatment for an increasingly common heart disease succeeded in a closely watched clinical trial, the company said Wednesday, clearing the path to approval and affirming the promise of a drug analysts expect to reap blockbuster sales.
    Patients treated with the intravenous drug, called patisiran, did significantly better than those taking a placebo on a test of how far they could walk over the course of six minutes, meeting the study's primary goal. The 12-month trial enrolled 360 patients with ATTR-CM, a progressive heart disease. The so-called six-minute walk test...
    Read more ...